1. Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa.
- Author
-
Sadek M, Le Guern R, Kipnis E, Gosset P, Poirel L, Dessein R, and Nordmann P
- Subjects
- Humans, Pseudomonas aeruginosa, Cephalosporins pharmacology, Cephalosporins therapeutic use, beta-Lactamases metabolism, Microbial Sensitivity Tests, Cefiderocol, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents metabolism, Pseudomonas Infections drug therapy, Pseudomonas Infections microbiology
- Abstract
We report in vivo development of cefiderocol (FDC) resistance among four sequential Pseudomonas aeruginosa clinical isolates ST244 recovered from a single patient, without exposure to FDC, which raises concern about the effectiveness of this novel drug. The first recovered P. aeruginosa isolate (P-01) was susceptible to FDC (2 μg/mL), albeit this MIC value was higher than that of a wild-type P. aeruginosa (0.12-0.25 μg/ml). The subsequent isolated strains (P-02, P-03, P-04) displayed increasing levels of FDC MICs (8, 16, and 64 μg/ml, respectively). Those isolates also showed variable and gradual increasing levels of resistance to most β-lactams tested in this study. Surprisingly, no acquired β-lactamase was identified in any of those isolates. Whole-genome sequence analysis suggested that this resistance was driven by multifactorial mechanisms including mutational changes in iron transporter proteins associated with FDC uptake, ampC gene overproduction, and mexAB-oprM overexpression. These findings highlight that a susceptibility testing to FDC must be performed prior to any prescription., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF